Insider Transactions in Q1 2025 at Amylyx Pharmaceuticals, Inc. (AMLX)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 31
2025
|
James M Frates Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,896
-3.61%
|
$32,688
$3.47 P/Share
|
|
Mar 31
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
9,192
-4.66%
|
$27,576
$3.48 P/Share
|
|
Mar 31
2025
|
Camille L Bedrosian Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,425
-6.01%
|
$37,275
$3.47 P/Share
|
|
Mar 31
2025
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
21,490
-0.64%
|
$64,470
$3.47 P/Share
|
|
Mar 31
2025
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
21,490
-0.64%
|
$64,470
$3.46 P/Share
|
|
Mar 20
2025
|
Bernhardt G Zeiher |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$30,000
$3.7 P/Share
|
|
Mar 06
2025
|
James M Frates Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,420
+18.48%
|
-
|
|
Mar 06
2025
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
180,118
+5.06%
|
-
|
|
Mar 06
2025
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
180,118
+5.06%
|
-
|
|
Mar 06
2025
|
Camille L Bedrosian Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,420
+24.86%
|
-
|
|
Mar 06
2025
|
Gina Mazzariello Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
63,851
+24.46%
|
-
|
|
Mar 03
2025
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,595
-0.14%
|
$13,785
$3.15 P/Share
|
|
Mar 03
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,611
-1.19%
|
$4,833
$3.12 P/Share
|
|
Mar 03
2025
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,595
-0.14%
|
$13,785
$3.17 P/Share
|
|
Feb 24
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,169
-3.0%
|
$12,507
$3.15 P/Share
|
|
Feb 05
2025
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,310
+1.12%
|
$36,310
$1.57 P/Share
|
|
Feb 03
2025
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,851
-0.37%
|
$35,553
$3.47 P/Share
|
|
Feb 03
2025
|
Gina Mazzariello Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,678
-2.58%
|
$11,034
$3.49 P/Share
|
|
Feb 03
2025
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,855
-0.37%
|
$35,565
$3.47 P/Share
|
|
Jan 24
2025
|
George M Milne Jr |
SELL
Bona fide gift
|
Direct |
27,910
-3.25%
|
-
|
|
Jan 06
2025
|
Justin B. Klee Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,471
-0.23%
|
$29,884
$4.04 P/Share
|
|
Jan 06
2025
|
Joshua B Cohen Co-Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
7,471
-0.23%
|
$29,884
$4.05 P/Share
|